MedImmune’s CytoGam
Executive Summary
Beginning Phase I/II trials for CMV in AIDS patients. The study of the cytomegalovirus immune globulin product is expected to be completed by September with Phase III efficacy trials projected to begin in autumn. CytoGam is already approved for the prevention of primary CMV in kidney transplant patients and Gaithersburg, Md.-based MedImmune will be seeking expanded labeling through submission of data on the use of the product to prevent CMV in liver transplant patients.